HK1159621A1 - Pyrazole derivatives used as ccr4 receptor antagonists - Google Patents

Pyrazole derivatives used as ccr4 receptor antagonists

Info

Publication number
HK1159621A1
HK1159621A1 HK12100042.4A HK12100042A HK1159621A1 HK 1159621 A1 HK1159621 A1 HK 1159621A1 HK 12100042 A HK12100042 A HK 12100042A HK 1159621 A1 HK1159621 A1 HK 1159621A1
Authority
HK
Hong Kong
Prior art keywords
receptor antagonists
pyrazole derivatives
derivatives used
ccr4 receptor
ccr4
Prior art date
Application number
HK12100042.4A
Other languages
English (en)
Inventor
Heather Hobbs
Simon Teanby Hodgson
Yannick Maurice Lacroix
Deborah Needham
Nigel James Parr
Panayiotis Alexandrou Procopiou
Timothy John Ritchie
Michael David Woodrow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1159621A1 publication Critical patent/HK1159621A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK12100042.4A 2009-02-26 2012-01-04 Pyrazole derivatives used as ccr4 receptor antagonists HK1159621A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15570209P 2009-02-26 2009-02-26
PCT/EP2010/052307 WO2010097395A1 (fr) 2009-02-26 2010-02-24 Dérivés pyrazole utilisés comme antagonistes du récepteur ccr4

Publications (1)

Publication Number Publication Date
HK1159621A1 true HK1159621A1 (en) 2012-08-03

Family

ID=42110309

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100042.4A HK1159621A1 (en) 2009-02-26 2012-01-04 Pyrazole derivatives used as ccr4 receptor antagonists

Country Status (31)

Country Link
US (3) US8304446B2 (fr)
EP (1) EP2401270B1 (fr)
JP (1) JP5520969B2 (fr)
KR (1) KR20110128896A (fr)
CN (1) CN102388039B (fr)
AR (1) AR075594A1 (fr)
AU (2) AU2010217629A1 (fr)
BR (1) BRPI1013396A2 (fr)
CA (1) CA2753337A1 (fr)
CL (1) CL2011002103A1 (fr)
CO (1) CO6420342A2 (fr)
DK (1) DK2401270T3 (fr)
DO (1) DOP2011000272A (fr)
EA (1) EA021740B1 (fr)
ES (1) ES2439773T3 (fr)
HK (1) HK1159621A1 (fr)
HR (1) HRP20131174T1 (fr)
IL (1) IL214655A0 (fr)
MA (1) MA33132B1 (fr)
MX (1) MX2011008972A (fr)
NZ (1) NZ594641A (fr)
PE (1) PE20120307A1 (fr)
PL (1) PL2401270T3 (fr)
PT (1) PT2401270E (fr)
RS (1) RS53133B (fr)
SG (1) SG173768A1 (fr)
SI (1) SI2401270T1 (fr)
SM (1) SMT201400001B (fr)
TW (1) TW201041879A (fr)
UY (1) UY32464A (fr)
WO (1) WO2010097395A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694401C (fr) 2007-08-31 2012-12-04 Eisai R&D Management Co., Ltd. Compose polycyclique
MX2011006782A (es) 2009-02-26 2011-07-20 Eisai R&D Man Co Ltd Sal de derivado de tetrahidrotriazolopiridina y un cristal de la misma.
MX2011008501A (es) 2009-02-26 2011-09-01 Eisai R&D Man Co Ltd Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide.
US8729260B2 (en) * 2010-05-19 2014-05-20 Savior Lifetec Corporation Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem
WO2012025473A1 (fr) * 2010-08-24 2012-03-01 Glaxo Group Limited Antagonistes du récepteur 4 des chimiokines cc
EP3107902B1 (fr) * 2014-02-20 2021-04-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Composés et procédés d'inhibition de la fascine
DK3490565T3 (da) * 2016-07-29 2022-07-11 Rapt Therapeutics Inc Azetidinderivater som chemokinreceptormodulatorer og anvendelser deraf
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
WO2018187509A1 (fr) 2017-04-04 2018-10-11 Flx Bio, Inc. Composés hétérocycliques utilisés en tant que modulateurs du récepteur de chimiokine
EP3609883B1 (fr) * 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Composés indazole substitués par fluor et leurs utilisations
BR112020009055A2 (pt) 2017-11-06 2020-11-03 Rapt Therapeutics, Inc. moduladores de receptor de quimiocina para tratamento de câncer positivo para vírus epstein barr
CN110028501B (zh) * 2018-01-12 2022-02-22 迈德欣国际有限公司 化合物及其制备方法和用途
IL276295B2 (en) 2018-01-26 2024-02-01 Rapt Therapeutics Inc Modulators of chemokine receptors and their uses
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用
US20230322741A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
CA2507948A1 (fr) * 2002-12-12 2004-07-29 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer

Also Published As

Publication number Publication date
CN102388039A (zh) 2012-03-21
US8507543B2 (en) 2013-08-13
WO2010097395A1 (fr) 2010-09-02
EA021740B1 (ru) 2015-08-31
US20120015932A1 (en) 2012-01-19
JP2012518673A (ja) 2012-08-16
DOP2011000272A (es) 2011-12-31
ES2439773T3 (es) 2014-01-24
HRP20131174T1 (hr) 2014-01-17
TW201041879A (en) 2010-12-01
PT2401270E (pt) 2014-01-20
MA33132B1 (fr) 2012-03-01
EP2401270A1 (fr) 2012-01-04
US8357716B2 (en) 2013-01-22
KR20110128896A (ko) 2011-11-30
CA2753337A1 (fr) 2010-09-02
US8304446B2 (en) 2012-11-06
CO6420342A2 (es) 2012-04-16
AU2010217629A1 (en) 2011-09-15
JP5520969B2 (ja) 2014-06-11
SI2401270T1 (sl) 2014-01-31
UY32464A (es) 2010-09-30
IL214655A0 (en) 2011-09-27
RS53133B (en) 2014-06-30
AR075594A1 (es) 2011-04-20
MX2011008972A (es) 2011-12-14
US20130030031A1 (en) 2013-01-31
SMT201400001B (it) 2014-03-07
AU2016203684A1 (en) 2016-06-23
CL2011002103A1 (es) 2012-02-24
CN102388039B (zh) 2015-07-15
US20100216860A1 (en) 2010-08-26
DK2401270T3 (da) 2014-01-13
PL2401270T3 (pl) 2014-03-31
NZ594641A (en) 2013-03-28
PE20120307A1 (es) 2012-04-04
EA201190142A1 (ru) 2012-05-30
EP2401270B1 (fr) 2013-10-16
BRPI1013396A2 (pt) 2016-03-29
SG173768A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
HK1159621A1 (en) Pyrazole derivatives used as ccr4 receptor antagonists
IL202657A0 (en) Imidazole derivatives as ccr2 receptor antagonists
IL205665A0 (en) Heteroaryl derivatives as orexin receptor antagonists
IL200804A0 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
IL201112A0 (en) Thiazolidine derivatives as orexin receptor antagonists
IL208355A0 (en) Heterocyclic copmpounds as adenosine receptor antagonist
EP2344497A4 (fr) Dérivés d'azaindole comme antagonistes du récepteur crth2
IL215690A0 (en) Thiazole derivatives and their use as p2y12 receptor antagonists
IL207846A0 (en) Arylsulfonyl pyrazoline carboxaidine derivatives as 5-ht6 antagonists
IL209264A0 (en) Heteroaromatic monoamides as orexinin receptor antagonists
EP2378877A4 (fr) Dérivés d'imidazolinone en tant qu'antagonistes de récepteurs cgrp
ZA201104873B (en) Quinazolinone derivatives useful as vanilloid antagonists
EP2480077A4 (fr) Pyrrolidines inédites utilisées en tant qu'antagonistes des récepteurs au glucagon, compositions en contenant et leurs procédés d'utilisation
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL207577A0 (en) Pyrrolidine ether derivatives as nk3 receptor antagonists
IL217759A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
HK1169992A1 (en) Pyrrolidine derivatives as nk - 3 receptor antagonists nk-3
IL213763A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
IL220554A (en) History of aminoalkylpyrimidine as histamine receptor antagonists 4h
IL210927A0 (en) 6-substituted benzoxazines as 5-ht-5a receptor antagonists
IL213769A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
ZA200809977B (en) Benzimidazole derivatives which are to be used as antagonist for the CB1 receptor
HRP20130657T1 (en) Imidazole derivatives as mglur5 antagonists
IL211803A0 (en) Quinazoline derivatives as nk3 receptor antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180224